Ann Arbor, MI – May 8, 2008

Genetics Squared’s Chief Medical Officer Selected
for the Sanford Project Advisory Council

Council’s Recommendation will Influence $400 Million Research Decisions

Contact: Eiler Communications: Jennifer@Eilerpr.com.

Peter F. Lenehan, MD, PhD, Chief Medical Officer for Ann Arbor based Genetics Squared, Inc., has been chosen to be a member of the Sanford Project Advisory Council. The Council is made up of a select group of clinicians, researchers, and senior executives and is charged with advising Sanford Health of Sioux Falls, South Dakota on its Sanford Project initiative.

The Sanford Project is one of four initiatives outlined by Sanford Health after a gift of $400 million from Mr. T. Denny Sanford in February 2007. The gift is the largest ever to a healthcare organization or hospital in America, as reported in the Sanford Health 2006/2007 Annual Report, and is the centerpiece of an integrated effort to transform Sanford Health from a regional healthcare provider to a world-class medical research organization with international clinical outreach programs. The Sanford Project will focus on a single pressing healthcare issue and will form a world-class research team dedicated to finding a cure.

The Advisory Council recently met to consider which of the four pressing healthcare issues would be the focus of the Sanford Project. The candidates were: Type I diabetes, human papillomavirus-related cancer, lupus, and pediatric multiple sclerosis. These four had previously been selected by Sanford officials, together with Ohio-based Battelle Technology Partnership Practice.

“I am honored to have been asked to assist in the long-term strategic development of Sanford Health”, said Dr. Lenehan. “Sanford is an emerging world-class healthcare organization that not only will conduct its own cutting-edge research but also will provide many unique collaborative opportunities for biotechnology and pharmaceutical companies, contract research organizations, and academic medical researchers throughout the Mid-West.”

Each of the thirteen Advisory Council members was chosen based on their broad experience in basic and clinical biomedical research, health systems design and management, translational medicine, and/or biotechnology and pharmaceutical development. Dr. Lenehan’s current role at Genetics Squared overseeing the clinical development and application of a wide range of disease prognostics and therapeutic diagnostics reflects his strong background in both basic and translational medical research. Immediately prior to joining Genetics Squared in 2005, he was Director, Clinical Development/Oncology at Pfizer Global Research & Development in Ann Arbor.

“We are pleased to have Dr. Lenehan assist us in our decision making.” said Ruth Krystopolski, VP of Growth & Development of Sanford Health. “The strength of our Advisory Council depends on the unique perspectives of each member. Peter’s contributions to our discussions are significant and greatly appreciated.”
The Advisory Council will make its recommendation to Sanford Health on which healthcare issue will be chosen. Sanford Health will announce the final selection on June 6.

About Sanford Health
Sanford Health is one of the few truly integrated, comprehensive health systems in the nation. Sanford believes its comprehensive, integrated and non-profit system model is the best and most sustainable way to deliver high quality and efficient healthcare. Sanford Health includes Sanford USD Medical Center, Sanford Clinic, Sanford Health Network, Sanford Health Plan and Sanford Health Foundation, all serving communities in South Dakota, Minnesota, Iowa and Nebraska.

About Genetics Squared, Inc.
Genetics Squared is a biotechnology company in Ann Arbor, Michigan that partners with clinical research organizations, pharmaceutical and biotechnology companies, research and development institutes, and academic centers to advance the reality of personalized medicine. The company uses its EvolverTM technology to develop proprietary rules (signatures) that aid in the development of diagnostics, prognostics, and therapeutics, with the goal of tailoring clinical management strategies to individuals and to improving patient stratification in clinical trials. Especially well suited for clinical oncology, Genetics Squared's technology has also been applied in other areas of clinical and preclinical biomedical research, such as infectious disease, nephrology, and autoimmune disease. For more information, please visit www.genetics2.com.